Replicate Design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2014-06-23 15:32 (4017 d 10:33 ago) – Posting: # 13125
Views: 5,391

Hello Naveen,

❝ Please suggest, can we design full replicate bioequivalence study (molecule is highly variable) in stages for EMEA submission.


Yes, that should be a possibility but:
  1. There are no publications about two-stage BE trials combined with replicated designs. You might be asked to prove by your own simulations that type I errors are controlled at max 5% or so.
  2. Don't do it without a meeting with FDA.

❝ My concern is Power will play pivotal role in stage design, which not be in replicate (full) designs.


Not understood - can you explain what you mean?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
25 visitors (0 registered, 25 guests [including 19 identified bots]).
Forum time: 02:06 CEST (Europe/Vienna)

Reach for the stars,
even if you have to stand on a cactus.    Susan Longacre

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5